Pre-made Enoblituzumab benchmark antibody ( Whole mAb, anti-CD276 therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-184
Pre-Made Enoblituzumab biosimilar, Whole mAb, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Enoblituzumab biosimilar, Whole mAb, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Conditions Active||Prostate cancer;Solid tumours;Head and neck cancer|
|Conditions Discontinued||Malignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer|